The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.

ABSTRACT: The monoclonal antibody rituximab improves clinical outcome in the treatment of CD20-positive lymphomatous neoplasms, and it is an established drug for treatment of these cancers. Successful mRNA COVID-19 (SARS-CoV-2) vaccination is extremely important for lymphoma patients because they tend to be elderly with comorbidities which leaves them at increased risk of poor outcomes once infected by Coronavirus. Anti-CD20 therapies such as rituximab, deplete B-cell populations and can affect vaccine efficacy. Therefore, a knowledge of the effect of COVID-19 vaccination in this group is critical. We followed a cohort of 28 patients with CD20-positive lymphomatous malignancies treated with rituximab that started prior to their course of COVID-19 vaccination, including boosters. We assayed for vacci

SUBMITTER: Komlodi-Pasztor E 

PROVIDER: S-EPMC11408186 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature